JP2023548136A5 - - Google Patents
Info
- Publication number
- JP2023548136A5 JP2023548136A5 JP2023526186A JP2023526186A JP2023548136A5 JP 2023548136 A5 JP2023548136 A5 JP 2023548136A5 JP 2023526186 A JP2023526186 A JP 2023526186A JP 2023526186 A JP2023526186 A JP 2023526186A JP 2023548136 A5 JP2023548136 A5 JP 2023548136A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- agonists
- product according
- linker
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108046P | 2020-10-30 | 2020-10-30 | |
| US63/108,046 | 2020-10-30 | ||
| US202163197935P | 2021-06-07 | 2021-06-07 | |
| US63/197,935 | 2021-06-07 | ||
| PCT/US2021/057291 WO2022094237A1 (en) | 2020-10-30 | 2021-10-29 | Enzyme activated serum extended half-life therapeutic conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548136A JP2023548136A (ja) | 2023-11-15 |
| JP2023548136A5 true JP2023548136A5 (https=) | 2024-09-20 |
Family
ID=81383295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526186A Pending JP2023548136A (ja) | 2020-10-30 | 2021-10-29 | 酵素活性化血清半減期延長型治療用コンジュゲート |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230381330A1 (https=) |
| EP (1) | EP4237011A4 (https=) |
| JP (1) | JP2023548136A (https=) |
| KR (1) | KR20230141755A (https=) |
| WO (1) | WO2022094237A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| WO2025259853A1 (en) * | 2024-06-12 | 2025-12-18 | Yale University | Multiplexed assemblies of proteins for targeted drug and gene delivery |
| WO2026002995A1 (en) | 2024-06-24 | 2026-01-02 | Avacta Life Sciences Limited | Target-specific fap-activated topoisomerase inhibitor conjugates and uses thereof |
| WO2026002988A1 (en) * | 2024-06-24 | 2026-01-02 | Avacta Life Sciences Limited | Fibroblast activation protein alpha binder proteins |
| CN119684406A (zh) * | 2024-12-18 | 2025-03-25 | 东南大学 | 一种荷载喜树碱的酶响应自组装多肽前药、其制备及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| RU2636046C2 (ru) * | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| CN106456799B (zh) * | 2014-06-03 | 2020-05-22 | 江苏佳瑞生物技术有限公司 | 肽-药物偶联物 |
| CN106573073B (zh) * | 2014-06-13 | 2021-09-28 | 塔夫茨大学信托人 | Fap激活的治疗剂以及其相关用途 |
| US20210353652A1 (en) * | 2018-06-04 | 2021-11-18 | Trustees Of Tufts College | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto |
| JP2023548310A (ja) * | 2020-10-30 | 2023-11-16 | アバクタ・ライフ・サイエンシーズ・リミテッド | Ｆａｐ活性化血清半減期延長型治療用コンジュゲート |
-
2021
- 2021-10-29 US US18/034,221 patent/US20230381330A1/en active Pending
- 2021-10-29 WO PCT/US2021/057291 patent/WO2022094237A1/en not_active Ceased
- 2021-10-29 JP JP2023526186A patent/JP2023548136A/ja active Pending
- 2021-10-29 EP EP21887614.2A patent/EP4237011A4/en active Pending
- 2021-10-29 KR KR1020237017997A patent/KR20230141755A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023548136A5 (https=) | ||
| AU2001275226B2 (en) | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | |
| EP2310029B1 (en) | Fusion proteins for use in the treatment of cancer | |
| AU2006260914B2 (en) | N, N-bis- (2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs | |
| JP2023548310A5 (https=) | ||
| US20180125988A1 (en) | Targeted xten conjugate compositions and methods of making same | |
| EP4417627A1 (en) | Recombinant fusion antibody, and antibody-drug conjugate and use thereof | |
| WO2019126240A1 (en) | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof | |
| AU2021297984B2 (en) | HER-2 targeted bispecific compositions and methods for making and using the same | |
| JP2008231107A (ja) | 抗血管新生性ポリペプチド及び血管新生を抑制するための方法 | |
| EP4090673A1 (en) | Cytokine il-2 prodrugs comprising a cleavable linker | |
| JP2023548136A (ja) | 酵素活性化血清半減期延長型治療用コンジュゲート | |
| TW202227139A (zh) | Fap活化之血清延長半衰期治療結合物 | |
| Gong et al. | Collagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy | |
| Su et al. | Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles | |
| WO2011005098A1 (en) | Peptide ligands for targeting to the blood-brain barrier | |
| RU2851152C1 (ru) | Нацеленные на her-2 биспецифические композиции и способы их получения и применения | |
| WO2026078691A1 (en) | Matrix metalloproteinase inhibitors and uses thereof | |
| Zuppone | Development of saporin-based therapeutic options for the treatment of solid tumors. | |
| Li et al. | Peptides as multifunctional linchpins in targeted drug conjugates | |
| WO2026080026A1 (en) | Antibody drug conjugates | |
| CN116963781A (zh) | 酶激活的血清延长半衰期治疗性缀合物 | |
| CN117042808A (zh) | Fap激活的血清延长半衰期治疗性缀合物 | |
| HK40007205A (en) | Fusion proteins for use in the treatemnt of cancer | |
| Ali-Hassan | The Development of Biological |